The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells
Open accessAbstract
Aluminum hydroxide (alum) and the oil-in-water emulsion MF59 are widely used, safe and effective adjuvants, yet their mechanism of action is poorly understood. We assessed the effects of alum and MF59 on human immune cells and found that both induce secretion of chemokines, such as CCL2 (MCP-1), CCL3 (MIP-1α), CCL4 (MIP-1β), and CXCL8 (IL-8), all involved in cell recruitment from blood into peripheral tissue. Alum appears to act mainly on macrophages and monocytes, whereas MF59 additionally targets granulocytes. Accordingly, monocytes and granulocytes migrate toward MF59-conditioned culture supernatants. In monocytes, both adjuvants lead to increased endocytosis, enhanced surface expression of MHC class II and CD86, and down-regulation of the monocyte marker CD14, which are all phenotypic changes consistent with a differentiation toward dendritic cells (DCs). When monocyte differentiation into DCs is induced by addition of cytokines, these adjuvants enhanced the acquisition of a mature DC phenotype and lead to an earlier and higher expression of MHC class II and CD86. In addition, MF59 induces further up-regulation of the maturation marker CD83 and the lymph node-homing receptor CCR7 on differentiating monocytes. Alum induces a similar but not identical pattern that clearly differs from the response to LPS. This model suggests a common adjuvant mechanism that is distinct from that mediated by danger signals. We conclude that during vaccination, adjuvants such as MF59 may increase recruitment of immune cells into the injection site, accelerate and enhance monocyte differentiation into DCs, augment Ag uptake, and facilitate migration of DCs into tissue-draining lymph nodes to prime adaptive immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Monocyte and macrophage heterogeneity
Gordon, S., & Taylor, P. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1733 · Cited by 5,190
Innate Immunity: The Virtues of a Nonclonal System of Recognition
Medzhitov, R., & Janeway, C. A. (1997) · Cell · doi:10.1016/s0092-8674(00)80412-2 · Cited by 2,434
The Instructive Role of Innate Immunity in the Acquired Immune Response
Fearon, D. T., & Locksley, R. M. (1996) · Science · doi:10.1126/science.272.5258.50 · Cited by 1,719
Boring, L., Gosling, J., Chensue, S. W., Kunkel, S. L., Farese, R. V., Broxmeyer, H. E., & Charo, I. F. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119798 · Cited by 1,096
IL-6 switches the differentiation of monocytes from dendritic cells to macrophages
Chomarat, P., Banchereau, J., Davoust, J., & Karolina Palucka, A. (2000) · Nature Immunology · doi:10.1038/82763 · Cited by 906
Castellino, F., Huang, A. Y., Altan-Bonnet, G., Stoll, S., Scheinecker, C., & Germain, R. N. (2006) · Nature · doi:10.1038/nature04651 · Cited by 855
Differentiation of Monocytes into Dendritic Cells in a Model of Transendothelial Trafficking
Randolph, G. J., Beaulieu, S., Lebecque, S., Steinman, R. M., & Muller, W. A. (1998) · Science · doi:10.1126/science.282.5388.480 · Cited by 809
Adjuvant-Enhanced Antibody Responses in the Absence of Toll-Like Receptor Signaling
Gavin, A. L., Hoebe, K., Duong, B., Ota, T., Martin, C., Beutler, B., & Nemazee, D. (2006) · Science · doi:10.1126/science.1135299 · Cited by 581
Recent advances in the discovery and delivery of vaccine adjuvants
O'Hagan, D. T., & Valiante, N. M. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1176 · Cited by 434
Self-citationDendritic Cells as the Terminal Stage of Monocyte Differentiation
Palucka, K. A., Taquet, N., Sanchez-Chapuis, F., & Gluckman, J. C. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.9.4587 · Cited by 378
Cited by
Vaccine Adjuvants: Putting Innate Immunity to Work
Coffman, R. L., Sher, A., & Seder, R. A. (2010) · Immunity · doi:10.1016/j.immuni.2010.10.002 · Cited by 1,924
mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555
Key roles of adjuvants in modern vaccines
Reed, S. G., Orr, M. T., & Fox, C. B. (2013) · Nature Medicine · doi:10.1038/nm.3409 · Cited by 1,419
Emerging concepts in the science of vaccine adjuvants
Pulendran, B., S. Arunachalam, P., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,385
Self-citationZhao, L., Seth, A., Wibowo, N., Zhao, C.-X., Mitter, N., Yu, C., & Middelberg, A. P. J. (2014) · Vaccine · doi:10.1016/j.vaccine.2013.11.069 · Cited by 919
Applications of nanotechnology for immunology
Smith, D. M., Simon, J. K., & Baker Jr, J. R. (2013) · Nature Reviews Immunology · doi:10.1038/nri3488 · Cited by 767
Mechanisms of Action of Adjuvants
Awate, S., Babiuk, L. A., & Mutwiri, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00114 · Cited by 732
New horizons in adjuvants for vaccine development
Reed, S. G., Bertholet, S., Coler, R. N., & Friede, M. (2009) · Trends in Immunology · doi:10.1016/j.it.2008.09.006 · Cited by 618
New horizons in adjuvants for vaccine development
Reed, S. G., Tomai, M., & Gale, M. J. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.08.008 · Cited by 554
The mechanism of action of MF59 – An innately attractive adjuvant formulation
O’Hagan, D. T., Ott, G. S., De Gregorio, E., & Seubert, A. (2012) · Vaccine · doi:10.1016/j.vaccine.2011.09.061 · Cited by 488
Self-citationMorel, S., Didierlaurent, A., Bourguignon, P., Delhaye, S., Baras, B., Jacob, V., Planty, C., Elouahabi, A., Harvengt, P., & Carlsen, H. (2011) · Vaccine · doi:10.1016/j.vaccine.2011.01.011 · Cited by 476
Use of defined TLR ligands as adjuvants within human vaccines
Duthie, M. S., Windish, H. P., Fox, C. B., & Reed, S. G. (2011) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00978.x · Cited by 437
Calabro, S., Tortoli, M., Baudner, B. C., Pacitto, A., Cortese, M., O’Hagan, D. T., De Gregorio, E., Seubert, A., & Wack, A. (2011) · Vaccine · doi:10.1016/j.vaccine.2010.12.090 · Cited by 433
Self-citationMechanism of Immunopotentiation and Safety of Aluminum Adjuvants
HogenEsch, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00406 · Cited by 430
Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity
Shi, S., Zhu, H., Xia, X., Liang, Z., Ma, X., & Sun, B. (2019) · Vaccine · doi:10.1016/j.vaccine.2019.04.055 · Cited by 423
New adjuvants for human vaccines
Mbow, M. L., De Gregorio, E., Valiante, N. M., & Rappuoli, R. (2010) · Current Opinion in Immunology · doi:10.1016/j.coi.2010.04.004 · Cited by 406
Squalene: A natural triterpene for use in disease management and therapy
Reddy, L. H., & Couvreur, P. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.09.005 · Cited by 397
Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want
HogenEsch, H., O’Hagan, D. T., & Fox, C. B. (2018) · npj Vaccines · doi:10.1038/s41541-018-0089-x · Cited by 391
Self-citationMechanism of action of clinically approved adjuvants
Lambrecht, B. N., Kool, M., Willart, M. A., & Hammad, H. (2009) · Current Opinion in Immunology · doi:10.1016/j.coi.2009.01.004 · Cited by 354
A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines
Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338
Self-citationAn Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives
Facciolà, A., Visalli, G., Laganà, A., & Di Pietro, A. (2022) · Vaccines · doi:10.3390/vaccines10050819 · Cited by 316
The history of MF59 ® adjuvant: a phoenix that arose from the ashes
O’Hagan, D. T., Ott, G. S., Nest, G. V., Rappuoli, R., & Giudice, G. D. (2013) · Expert Review of Vaccines · doi:10.1586/erv.12.140 · Cited by 313
Self-citationUnleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants
Maisonneuve, C., Bertholet, S., Philpott, D. J., & De Gregorio, E. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1400478111 · Cited by 303
Metalloimmunology: The metal ion-controlled immunity
(2020) · Advances in Immunology · doi:10.1016/bs.ai.2019.11.007 · Cited by 292
Adjuvants: Classification,Modus Operandi, and Licensing
Apostólico, J. D. S., Lunardelli, V. A. S., Coirada, F. C., Boscardin, S. B., & Rosa, D. S. (2016) · Journal of Immunology Research · doi:10.1155/2016/1459394 · Cited by 287
The path to a successful vaccine adjuvant – ‘The long and winding road’
O’Hagan, D. T., & De Gregorio, E. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.02.009 · Cited by 274
Self-citationPlant Sources, Extraction Methods, and Uses of Squalene
Lozano-Grande, M. A., Gorinstein, S., Espitia-Rangel, E., Dávila-Ortiz, G., & Martínez-Ayala, A. L. (2018) · International Journal of Agronomy · doi:10.1155/2018/1829160 · Cited by 270
Shaw, C. A., & Tomljenovic, L. (2013) · Immunologic Research · doi:10.1007/s12026-013-8403-1 · Cited by 269
Tregoning, J. S., Russell, R. F., & Kinnear, E. (2018) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2017.1415684 · Cited by 263
Erasmus, J. H., Khandhar, A. P., Guderian, J., Granger, B., Archer, J., Archer, M., Gage, E., Fuerte-Stone, J., Larson, E., Lin, S., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.07.010 · Cited by 161
“Mip-1b ELISA was performed as previously described.(44)”
MethodGohil, N., Bhattacharjee, G., Khambhati, K., Braddick, D., & Singh, V. (2019) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2019.00050 · Cited by 121
“Although the exact biological mechanism is not yet clear, it is predicted that MF59 elicits an immune response by recruiting the phagocytic cells to the site of delivery, promoting maturation of monocytes into dendritic cells, and facilitating their transport to nearby lymph nodes to trigger the adaptive immune respon…”
BackgroundKamalov, J., Carpenter, D. O., & Birman, I. (2011) · Journal of Toxicology · doi:10.1155/2011/796719 · Cited by 11
Metadata
- Authors
- Seubert, A., Monaci, E., Pizza, M., O’Hagan, D. T., & Wack, A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-04
- Volume
- 180
- Issue
- 8
- Pages
- 5402-5412
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1543572242
- Cited by
- 430
- References
- 35
- FWCI
- 10.54
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.